Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CM512 injection with background therapy in perennial allergic rhinitis
CTR20263862Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM512 in perennial rhinitis, sponsored by Keymed Biosciences. Started Oct 2026; status: active.
02
Drugs
CM512
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on CTR20263862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263862.